The polyclonal antibody Anti-Vitronectin V65 subunit [pAb-V65] was developed and validated for the measurement of V65 in patient serum.
| Inventor | Institute |
|---|---|
| Mohammed Sharif | University of Bristol |
| Cat. #: | 153621 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Immunology;Tissue-specific biology |
| Application: | ELISA ; WB |
| Target: | Vitronectin V65 subunit |
| Reactivity: | Human |
| Clone: | pAb-V65 |
| Host: | Rabbit |
| Class: | Polyclonal |
| Alternate name: | Complement S Protein antibody, Epibolin antibody, S Protein antibody, Serum Spreading Factor antibody, Somatomedin B antibody, Vitronectin V65 subunit antibody, VN antibody, VNT antibody, VTNC_HUMAN antibody |
|---|---|
| Product description: | Osteoarthritis (OA) is the most common chronic joint disease usually diagnosed at relatively advanced stages when there is irreparable damage to the joint(s). Recently, two novel biomarkers C3f and V65 were identified which appear to be OA-specific and therefore potential markers of early disease. The polyclonal antibody Anti-Vitronectin V65 subunit [pAb-V65] was developed and validated for the measurement of V65 in patient serum. |
| Conjugation: | Unconjugated |
| Immunogen: | V65 peptide-carrier conjugate. The carrier protein is Keyhole Limpet Haemocyanin (KLH). |
| Target background: | Osteoarthritis (OA) is the most common chronic joint disease usually diagnosed at relatively advanced stages when there is irreparable damage to the joint(s). Recently, two novel biomarkers C3f and V65 were identified which appear to be OA-specific and therefore potential markers of early disease. The polyclonal antibody Anti-Vitronectin V65 subunit [pAb-V65] was developed and validated for the measurement of V65 in patient serum. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Ourradi et al. 2017. PLoS One. 12(7):e0181334. PMID: 28715494. Development and validation of novel biomarker assays for osteoarthritis. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151016 | Anti-CyclinA [E72.1] |
Key Info
Anti-CyclinA [E72.1]
|
View Tool | |||||||||||||||||||
| 151036 | Anti-ICAM1 [15.2] |
Key Info
Anti-ICAM1 [15.2]
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
| 151018 | Anti-Mos [R38.1] |
Key Info
Anti-Mos [R38.1]
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.